Real-world Treatment Patterns Among Patients With Chemotherapy-induced Peripheral Neuropathy in China: The Retrospective, Observational ReTARdant Study
Xiaoyu Zhai1, Peng Mao2, Yanxia Shi3, Huihui Li4, Guohua Ren4, Tao Sun5, Yangyang Duan5, Yingchun Zhang6, Na Guo6, Min Li6, Bifa Fan2, Jun Zhao1
1Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer Hospital and Institute, 2Department of Pain Medicine, China-Japan Friendship Hospital, 3Department of Medical Oncology, Sun Yat-sen University Cancer Center, 4Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 5Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, 6Medical Affairs Department, Daiichi Sankyo (China) Holdings Co., Ltd
Objective:
To investigate pharmacological treatment patterns in the real-world setting among patients with chemotherapy-induced peripheral neuropathy (CIPN) in China.
Background:
CIPN is one common adverse effect of neurotoxic chemotherapy, and current treatment patterns among Chinese patients with CIPN remain unclear.
Design/Methods:
This retrospective, observational study (NCT06546202) was based on electronic medical records from 5 hospitals in China. Patients who were diagnosed with CIPN and received index regimens between January 1, 2018, to December 31, 2021, were identified. Targeted regimens included tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, calcium channel ligands [CaLs], sodium channel blockers, nonsteroidal anti-inflammatory drugs [NSAIDs], opioids, and neuropathic drugs [NeuDs]. Data were collected from the index date (the initiation date of the index regimens) to December 31, 2022. Patient characteristics and treatment patterns were summarized with descriptive statistics.
Results:
A total of 451 patients (mean age ± standard deviation, 56.6 ± 11.2 years; male, 56.5%; stage IV tumors, 40.4%; treatment naïve for CIPN, 45.7%) with CIPN were included. The common primary tumors were lung cancer (n=103, 22.8%), colorectal cancer (n=82, 18.2%), and breast cancer (n=74, 16.4%). At the index date, opioids (n=176, 39.0%), NSAIDs (n=163, 36.1%), NeuDs (n=154, 34.2%), and CaLs (n=108, 24.0%) were most frequently prescribed, with NeuDs (n=123, 27.3%) and NSAIDs+opioids (n=53, 11.8%) being the most common monotherapy and combination therapy, respectively. During observation period, treatment discontinuation, switch, and add-on of the index treatment were observed in 445 (98.7%), 106 (23.5%), and 53 (11.8%) patients, respectively. The discontinuation rates of the index treatment regimens were 83.5% at 30 days and 92.8% at 60 days.
Conclusions:
In Chinese patients with CIPN, opioids, NSAIDs, NeuDs, and CaLs were the most commonly prescribed regimens. Treatment discontinuation was frequent. There is a need to improve treatment strategies for CIPN in clinical practice in China.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.